TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7926247

Group type: EXPERIMENTAL
Intervention: Double balloon catheter
Number of subjects: 20

Group type: COMPARATOR
Intervention: Extra-amniotic PGF2-alpha
Number of subjects: 20
Study: 2680178

Group type: EXPERIMENTAL
Intervention: Betamethasone dipropionate cream twice daily
Number of subjects: 97

Group type: COMPARATOR
Intervention: Betamethasone dipropionate cream once daily with base cream in the evening
Number of subjects: 97
Study: 765293

Group type: EXPERIMENTAL
Intervention: Cyclazocine, 4 mg administered daily
Number of subjects: 70

Group type: COMPARATOR
Intervention: Naloxone, 500-2,000 mg administered on a contingent basis
Number of subjects: 70
Study: 31981645

Group type: EXPERIMENTAL
Intervention: Omni Mode
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal Mode
Number of subjects: 0
Study: 30977392

Group type: EXPERIMENTAL
Intervention: Transcutaneous nerve stimulation + standard early rehabilitation
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation + standard early rehabilitation
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard early rehabilitation-only
Number of subjects: 42
Study: 27926647

Group type: EXPERIMENTAL
Intervention: Computer analysis and online alerts (experimental arm)
Number of subjects: 7730

Group type: COMPARATOR
Intervention: Visual analysis (control arm)
Number of subjects: 7730
Study: 25996181

Group type: EXPERIMENTAL
Intervention: Interactive text messaging intervention
Number of subjects: 160
Study: 23360810

Group type: EXPERIMENTAL
Intervention: Checklist used during handover
Number of subjects: 120

Group type: COMPARATOR
Intervention: No checklist used during handover
Number of subjects: 120
Study: 21303569

Group type: EXPERIMENTAL
Intervention: Fe-fortified fruit juice (500 ml/d providing 18 mg Fe/d)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo fruit juice (500 ml/d)
Number of subjects: 122
Study: 19494532

Group type: EXPERIMENTAL
Intervention: Metformin (1,700 mg/day) for 12 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 mg/day) for 12 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Simvastatin (maximum dose 20 mg/day) in a subset of patients (n = 9)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Healthy controls (n = 23)
Number of subjects: 40
Study: 17719288

Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 8335

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8335

Group type: EXPERIMENTAL
Intervention: ACE inhibitors (including ramipril)
Number of subjects: 8335
Study: 15576217

Group type: EXPERIMENTAL
Intervention: Trapeziectomy with palmaris longus interposition
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Trapeziectomy with ligament reconstruction and tendon interposition
Number of subjects: 183

Group type: COMPARATOR
Intervention: Simple trapeziectomy
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 183
Study: 12508627

Group type: EXPERIMENTAL
Intervention: Directly Observed Therapy Short Course (DOTS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self Administered Therapy (SAT)
Number of subjects: 0
Study: 9660578

Group type: EXPERIMENTAL
Intervention: Pentoxifylline 400 mg three times daily
Number of subjects: 28
Study: 7861604

Group type: EXPERIMENTAL
Intervention: Portex Spinal/Epidural set (P needles)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Hakko Disposable Needles set type H (H needles)
Number of subjects: 30
Study: 2499169

Group type: EXPERIMENTAL
Intervention: Encainide
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 18

Group type: COMPARATOR
Intervention: Both drugs
Number of subjects: 18
Study: 799567

Group type: EXPERIMENTAL
Intervention: Minoxidil
Number of subjects: 20
Study: 31564264

Group type: EXPERIMENTAL
Intervention: Traditional TAPP (T‐TAPP)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Modified TAPP (M‐TAPP)
Number of subjects: 62
Study: 27861261

Group type: EXPERIMENTAL
Intervention: Standard ventilation with a recruitment manoeuvre and 10 cmH2O of PEEP after surgery (group RM, n=20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard ventilation with 6 cmH2O of positive end-expiratory pressure (PEEP; group C, n=20)
Number of subjects: 40
Study: 26279206

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment
Number of subjects: 26

Group type: COMPARATOR
Intervention: Untreated children
Number of subjects: 26
Study: 24026211

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 1284

Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 1284

Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg
Number of subjects: 1284

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1284
Study: 21890882

Group type: EXPERIMENTAL
Intervention: AP Advance (APA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 0

Group type: COMPARATOR
Intervention: GlideScope Ranger
Number of subjects: 0
Study: 19473611

Group type: EXPERIMENTAL
Intervention: PEPA dialyzer
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: PS dialyzer
Number of subjects: 47
Study: 17950105

Group type: EXPERIMENTAL
Intervention: Atorvastatin (average dosage, 20.8 mg/d)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Fenofibrate (200 mg/d)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 56

Group type: COMPARATOR
Intervention: Fenofibrate
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Atorvastatin and Fenofibrate
Number of subjects: 56

Group type: COMPARATOR
Intervention: FCHL patients compared to normolipemic controls
Number of subjects: 56
Study: 15146262

Group type: EXPERIMENTAL
Intervention: Tazarotene 0.1% cream
Number of subjects: 562

Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 562
Study: 11330756

Group type: EXPERIMENTAL
Intervention: Usual rehabilitation programme (group A)
Number of subjects: 239

Group type: COMPARATOR
Intervention: Control group (group B)
Number of subjects: 239
Study: 9205766

Group type: EXPERIMENTAL
Intervention: Ebrotidine 800 mg/d p.o. (Group A)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Indometacin 4 mg/kg/d p.o. in 3 divided doses (Group B)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ebrotidine 800 mg/d p.o. plus Indometacin 4 mg/kg/d p.o. (Group C)
Number of subjects: 18
Study: 8280546

Group type: EXPERIMENTAL
Intervention: Background infusion 10 micrograms kg-1 h-1 (B10)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Background infusion 4 micrograms kg-1 h-1 (B4)
Number of subjects: 45

Group type: COMPARATOR
Intervention: No background infusion (B0)
Number of subjects: 45
Study: 3329963

Group type: EXPERIMENTAL
Intervention: Clindamycin + Aztreonam
Number of subjects: 62

Group type: COMPARATOR
Intervention: Clindamycin + Gentamicin
Number of subjects: 62
Study: 29104008

Group type: EXPERIMENTAL
Intervention: Pharmacist-led intervention emphasizing compliance, smoking cessation, exercise, inhaler use, and timely follow-up.
Number of subjects: 260

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 260
Study: 26771733

Group type: EXPERIMENTAL
Intervention: Eptifibatide (bolus plus infusion) 12-48 hours prior to surgery (N=72 patients)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo (normal saline; N=68 patients)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Eptifibatide (bolus plus infusion)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 140
Study: 24345886

Group type: EXPERIMENTAL
Intervention: 56.5 μg teriparatide
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 22652160

Group type: EXPERIMENTAL
Intervention: Oxybutynin (5 mg) + Trospium Chloride (20 mg) administered 3 times a day and 4 times a day respectively in Group A
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oxybutynin (5 mg) + Solifenacin (10 mg) administered 3 times a day and once daily respectively in Group B
Number of subjects: 12
Study: 19933512

Group type: EXPERIMENTAL
Intervention: Huffing manoeuvre before i.v. fentanyl (2.5 microg kg(‐1))
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group (normal breathing before i.v. fentanyl (2.5 microg kg(‐1)))
Number of subjects: 300
Study: 17392649

Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate (RBC, 400 mg b.d.), esomeprazole (40 mg/day), amoxycillin (1 g t.d), and tinidazole (500 mg b.d.) with bovine lactoferrin (200 mg b.d)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Ranitidine bismuth citrate (RBC, 400 mg b.d.), esomeprazole (40 mg/day), amoxycillin (1 g t.d), and tinidazole (500 mg b.d.) without bovine lactoferrin
Number of subjects: 70
Study: 16118569

Group type: EXPERIMENTAL
Intervention: Most active women (vigorous physical activity 10-12 months x yr) during high school and age 18-22 yr
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: Most active women (> or = 1500 kcal x wk(‐1))
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: Physical activity during young adulthood
Number of subjects: 477
Study: 14622730

Group type: EXPERIMENTAL
Intervention: Developmental care
Number of subjects: 19
Study: 10197573

Group type: EXPERIMENTAL
Intervention: Tomato diet (16.5 mg lycopene)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Tomato-free diet
Number of subjects: 10
Study: 7767241

Group type: EXPERIMENTAL
Intervention: Monthly feedback with peer comparison
Number of subjects: 179
Study: 1430964

Group type: EXPERIMENTAL
Intervention: Endoscopic device for carpal tunnel release
Number of subjects: 122

Group type: COMPARATOR
Intervention: Conventional open surgery
Number of subjects: 122
Study: 3902512

Group type: EXPERIMENTAL
Intervention: HTF medium
Number of subjects: 113

Group type: COMPARATOR
Intervention: T6 medium
Number of subjects: 113
Study: 30580275

Group type: EXPERIMENTAL
Intervention: CRC screening participants (faecal immunochemical test: n=958; colonoscopy: n=298)
Number of subjects: 1409

Group type: COMPARATOR
Intervention: Non-participants in CRC screening
Number of subjects: 1409

Group type: EXPERIMENTAL
Intervention: Higher anxiety levels
Number of subjects: 1409

Group type: EXPERIMENTAL
Intervention: Lower anxiety levels
Number of subjects: 1409
Study: 27614452

Group type: EXPERIMENTAL
Intervention: Photoelectric and musical treatment group (Group 1)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Acupuncture group (Group 2)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Oral placebo group (Group 3)
Number of subjects: 174
Study: 25554976

Group type: EXPERIMENTAL
Intervention: Pay for performance scheme
Number of subjects: 0
Study: 23083636

Group type: EXPERIMENTAL
Intervention: GnRH antagonist
Number of subjects: 141

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 141
Study: 19280340

Group type: EXPERIMENTAL
Intervention: Chemoendocrine therapy
Number of subjects: 1850

Group type: COMPARATOR
Intervention: Endocrine therapy alone
Number of subjects: 1850
Study: 18629567

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention (mailed reminder, treatment guidelines, educational package)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 270
Study: 16775668

Group type: EXPERIMENTAL
Intervention: Xuezhikang (XZK) 1,200 mg daily for 6 weeks, then replaced by placebo (XZK discontinued group; n = 25)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Xuezhikang (XZK) 1,200 mg daily throughout the study (XZK continued group; n = 25)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo (no XZK group; n = 25)
Number of subjects: 75
Study: 15030293

Group type: EXPERIMENTAL
Intervention: Ezetimibe (Zetia) as monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ezetimibe coadministered with statins (simvastatin, atorvastatin, lovastatin, or pravastatin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ezetimibe plus statin coadministration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Statin monotherapy
Number of subjects: 0
Study: 10944137

Group type: EXPERIMENTAL
Intervention: High-dose therapy (HDT) using cyclophosphamide, carmustine, and etoposide (CBV regimen) followed by stem-cell transplantation
Number of subjects: 236

Group type: COMPARATOR
Intervention: Sequential chemotherapy (ifosfamide plus etoposide, asparaginase, and cytarabine)
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: High-dose therapy (HDT)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Sequential chemotherapy
Number of subjects: 236
Study: 8596127

Group type: EXPERIMENTAL
Intervention: co-amoxiclav (amoxicillin 875 mg + clavulanic acid 125 mg) twice daily for 10 days
Number of subjects: 218

Group type: COMPARATOR
Intervention: cefixime (400 mg) once daily for 10 days
Number of subjects: 218

Group type: COMPARATOR
Intervention: ciprofloxacin (500 mg) twice daily for 10 days
Number of subjects: 218
Study: 2172578

Group type: EXPERIMENTAL
Intervention: Enrich (12.8 g of dietary fiber per 1000 kcal)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Ensure (fiber-free)
Number of subjects: 28
Study: 365212

Group type: EXPERIMENTAL
Intervention: TRAP
Number of subjects: 250

Group type: COMPARATOR
Intervention: BARTS III
Number of subjects: 250
Study: 31857621

Group type: EXPERIMENTAL
Intervention: Kazakh students
Number of subjects: 7096

Group type: EXPERIMENTAL
Intervention: Uygur students
Number of subjects: 7096

Group type: EXPERIMENTAL
Intervention: Han students
Number of subjects: 7096

Group type: EXPERIMENTAL
Intervention: Normal weight, overweight, and obesity groups
Number of subjects: 7096
Study: 27853926

Group type: EXPERIMENTAL
Intervention: 1 mA anodal tDCS over the left dorsolateral prefrontal cortex
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sham protocol
Number of subjects: 15
Study: 26445227

Group type: EXPERIMENTAL
Intervention: Combination of Iodine-125 brachytherapy and DP regimen (docetaxel 60 mg/m²/cisplatin 75 mg/m²)
Number of subjects: 52

Group type: COMPARATOR
Intervention: DP chemotherapy
Number of subjects: 52
Study: 23570818

Group type: EXPERIMENTAL
Intervention: Expectancy challenge intervention
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 96
Study: 21226782

Group type: EXPERIMENTAL
Intervention: Pros enhancement intervention
Number of subjects: 1436

Group type: COMPARATOR
Intervention: Education session (control)
Number of subjects: 1436
Study: 18663661

Group type: EXPERIMENTAL
Intervention: CPAP treatment
Number of subjects: 400

Group type: COMPARATOR
Intervention: Non-CPAP treatment
Number of subjects: 400
Study: 17229894

Group type: EXPERIMENTAL
Intervention: 1000 mg of DHA
Number of subjects: 116

Group type: COMPARATOR
Intervention: 1252 mg of DHA + EPA
Number of subjects: 116
Study: 14637268

Group type: EXPERIMENTAL
Intervention: Urate 1000 mg intravenously over 1 h
Number of subjects: 34

Group type: COMPARATOR
Intervention: Vitamin C 1000 mg intravenously over 1 h
Number of subjects: 34
Study: 10618558

Group type: EXPERIMENTAL
Intervention: Tranilast (300 and 450 mg twice daily for 1 or 3 months)
Number of subjects: 11500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11500
Study: 9414347

Group type: EXPERIMENTAL
Intervention: Different rifle designs
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Aiming stability
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Aiming fluctuations
Number of subjects: 12
Study: 8500334

Group type: EXPERIMENTAL
Intervention: trifluridine
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: dexamethasone
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: artificial tears
Number of subjects: 74
Study: 2834500

Group type: EXPERIMENTAL
Intervention: Kabi 2165 (n = 40): 2,500 U anti‐Xa preoperatively and evening of operation and 2,500 U anti‐Xa morning and evening daily up to the 9th or 10th day postoperatively
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard heparin (n = 40): 3,750 U preoperatively and then 8 hourly, adjusted with thrombin time and cephalin + activator time, daily up to the 9th or 10th day
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Overall tolerance evaluated from hemoglobin and hematocrit values, intra‐ and post‐operative bleeding, operation wound hematoma, and injection site
Number of subjects: 80
Study: 30031988

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 49
Study: 27023086

Group type: EXPERIMENTAL
Intervention: TNF-α inhibitors
Number of subjects: 0
Study: 25057084

Group type: EXPERIMENTAL
Intervention: S-1 maintenance chemotherapy (40 mg/m², twice daily for 14 days; 21 days for a treatment cycle)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: S-1 maintenance chemotherapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Optimal supportive care
Number of subjects: 60
Study: 22049088

Group type: EXPERIMENTAL
Intervention: Received a letter informing them that the results of the trial could be consulted on a specific website.
Number of subjects: 107

Group type: COMPARATOR
Intervention: Did not receive a letter informing them about the trial results.
Number of subjects: 107
Study: 21170108

Group type: EXPERIMENTAL
Intervention: Sequential therapy (lamivudine 100 mg/d for 32 weeks + interferon alpha 2b 5 million units every other day for 24 weeks)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Lamivudine monotherapy (100 mg/d for 48 weeks)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Interferon monotherapy (5 million units every other day for 24 weeks)
Number of subjects: 225
Study: 18243244

Group type: EXPERIMENTAL
Intervention: Moderate-high exercise
Number of subjects: 4683

Group type: COMPARATOR
Intervention: Low exercise
Number of subjects: 4683
Study: 15732268

Group type: EXPERIMENTAL
Intervention: Story Memory Technique (SMT)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Memory exercises (Control)
Number of subjects: 29
Study: 12957262

Group type: EXPERIMENTAL
Intervention: Radiation therapy delay of 0-9 days
Number of subjects: 1226

Group type: COMPARATOR
Intervention: Radiation therapy delay of 10+ days
Number of subjects: 1226
Study: 9888081

Group type: EXPERIMENTAL
Intervention: 2-site group (mitomycin-C trabeculectomy with phacoemulsification through a separate incision)
Number of subjects: 76

Group type: COMPARATOR
Intervention: 1-site group (mitomycin-C trabeculectomy with phacoemulsification through the same incision)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: 2-site group
Number of subjects: 76

Group type: COMPARATOR
Intervention: 1-site group
Number of subjects: 76
Study: 9034556

Group type: EXPERIMENTAL
Intervention: Saruplase (80 mg)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Urokinase (3 million units)
Number of subjects: 230
Study: 1848607

Group type: EXPERIMENTAL
Intervention: Thallium‐201‐diethyldithiocarbamate SPECT imaging within 24 hours after stroke
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Thallium‐201‐diethyldithiocarbamate SPECT imaging at 2 weeks after stroke
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Thallium‐201‐diethyldithiocarbamate SPECT imaging at 6 months after stroke
Number of subjects: 26

Group type: COMPARATOR
Intervention: Calcium‐entry blocker flunarizine (random treatment)
Number of subjects: 26
Study: 6391611

Group type: EXPERIMENTAL
Intervention: 1 per cent silver sulfadiazine plus 0.2 per cent chlorhexidine digluconate (Silvazine)
Number of subjects: 121

Group type: COMPARATOR
Intervention: 1 per cent silver sulfadiazine (Flamazine)
Number of subjects: 121
Study: 31256255

Group type: EXPERIMENTAL
Intervention: Stent anastomosis (SA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Quality of life (QOL) assessment
Number of subjects: 60
Study: 30309994

Group type: EXPERIMENTAL
Intervention: CGA-based outpatient care in addition to usual care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 0
Study: 26609642

Group type: EXPERIMENTAL
Intervention: Tutomesh TUTOGEN biological prosthesis reinforcement parietal herniorrhaphy (Group B)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Simple parietal herniorrhaphy without prosthetic reinforcement (Group A)
Number of subjects: 134
Study: 25275513

Group type: EXPERIMENTAL
Intervention: IgA neutralization
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: α-defensins and secretory leukocyte protease inhibitor (SLPI) levels
Number of subjects: 208
Study: 22510426

Group type: EXPERIMENTAL
Intervention: 10 weekly individual child CBT sessions and 2 parent sessions
Number of subjects: 204

Group type: COMPARATOR
Intervention: minimal information
Number of subjects: 204
Study: 19460773

Group type: EXPERIMENTAL
Intervention: G‐CSF (5 microg/kg, twice a day for 3 days)
Number of subjects: 74
Study: 17515447

Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 15300574

Group type: EXPERIMENTAL
Intervention: Fecal COX‐2 assay
Number of subjects: 51

Group type: COMPARATOR
Intervention: Fecal CEA assay
Number of subjects: 51
Study: 11594100

Group type: EXPERIMENTAL
Intervention: Positive therapeutic message audiotape
Number of subjects: 27

Group type: COMPARATOR
Intervention: Blank (Controls)
Number of subjects: 27
Study: 9791046

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (0, 2 and 4 pmol.min‐1.kg‐1 for 1 h each)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: C-type natriuretic peptide (0, 2 and 4 pmol.min‐1.kg‐1 for 1 h each)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 7988254

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 328

Group type: COMPARATOR
Intervention: No surgery
Number of subjects: 328
Study: 2729751

Group type: EXPERIMENTAL
Intervention: Theophylline after resistive breathing
Number of subjects: 8

Group type: COMPARATOR
Intervention: Inspiratory flow resistive loads (4.5 to 27.0 cm H2O/L/s)
Number of subjects: 8
Study: 30486858

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention (MCI)
Number of subjects: 2550

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2550
Study: 28426123

Group type: EXPERIMENTAL
Intervention: Cabozantinib (100 mg daily for 12 weeks)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Cabozantinib (after randomization)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo (after randomization)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Cabozantinib (overall)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Cabozantinib (in patients with elevated baseline AFP)
Number of subjects: 41